Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Neal, have you heard from Rosalind. The data read seemed good to me. Unsure of the market reaction. The safety is in line and appears no unmanageable treatment related reactions.
They had a net loss of $7.0m for the qtr ending in dec. They had a net gain of $12.5m for the same period ending in 2019!
Got lucky and picked some up at $9.90 pm!
I am a big buyer today
I am a big buyer today
Probably update on p3 on 3/31 quarterly call.
Anyone have any updates on when results will be posted. Nearing the end of the quarter now.
17.92--- we seem to be on track with Gerard!
Yes--- still buying here.
I am also veryyyy wary.
P3s have been great... and NOT.
I am not comfortable that wrapping up P3 is still a problem so will preliminary be by end of March or 1st week of April, I don't know. It is a risk and efficacy is an open question too, certainly some efficacy but we wait. On the other hand $17 or $18 is worth some money
Does anyone know how the trial results are going???
This drop is not assuring... to me.
Chart looks terrible...
I think it is premature to worry about the trading. I have some concerns fundamentally, but $30 seems very possible if P3 is reasonable. The smallest of my concerns though is safety of treatment, safety is super
17-- why down so much from the high?
doubled from $9 after speaking with Rosalind, but now lost all the value above...
doc (MD, IR) is back on IV DCTH, positive!!!!!!!!!!!!!!!!!
We are BUYING.
$30 would be very nice--- Love Actually!
I lost a ton when SRRA results did not come in well, so be careful!
I expect the price to go over $30 on just reasonably okay P3 reported
Bought on the pull back today.
Lots of things to like
Low float
Platform technology
Rare indication
Derisked p3 based on published studies
1000+ procedures performed
Real benefit to patients fighting cancer
New management team trying to build trust. CEO interview seemed to indicate knowledge and honesty
20.04---bought more.
Me too... I lost a ton of $ with SRRA!!!
But let me know when to buy SRRA again :)
As for DCTH--- here's hoping! It could be great...
or not...
I like TO a lot--- go to the Film Festivals there!
Call me any time 212-666-6217--- and check out ONCY,
also from friend in Canada. PCLOF. There are several.
Thanks, Neal Hugh Hurwitz, NY NY (DCTH)/ Medellin (PCLOF)/ Israel (NNDM, DRIO, ENLV, etc.)
Can't go wrong with us Toronto peeps ;)
SRR@ will have it's day and a decent looking base set-up forming over the last year. So worth keeping an eye on.
But I'd rather be here
GL
It really feels like all or nothing... the all is a lot but the downside is there if the trial results are not seen as positive for FDA approval.
Given everything we think we know now about the tech, we are buying. Read doc on IV.
GL!--- this can be great, or a real bummer (I had that with SRRA!).
I AM upset that Jim Pingpank does not return my calls anymore... :( porque? JP and Alexander go back with this to the start at NIH.
PS--- I like Gil at Rosalind in Toronto, fwiw :)
Nicely. Im gonna gobble some to start the week @ $20 and any slight dips below
GL
It has been slipping from $24 high to $20 now... but I got here again at $9 so waiting... a bit.
There is no news.
Same here. Thank you for your time. Let’s go DCTH.
Good to speak. Thanks!
Let's see how we do with this!!!
Thank you, that is great to hear. I was in early and have bought it up off the bottom thru $20. Got a nice average now and just waiting.
Looking forward to the updates.
One report I have says trial results are good, but who knows!!!?
Agreed. The pain of the past is over.
The value is about to shown in the coming months ahead and I personally think the way this chart is set up is going to blow minds
Look forward to seeing the story unfold.
Best of luck!
Well......... all seems OK ahead so far.
We got in at $9 after I spoke with Rosalind.
It recovered well AH on Friday as sam noted.
My IR MD friend has been in this for many years--- likes the tech. So does Jonathan Zager, using it at Moffitt in FL. They also use it in Europe.
FDA approval is possible in 2021...
Commercialization 2022.
It is either/or... with great potential.
Stock history is terrible but we are past that now.
TY, Neal Hugh Hurwitz, NY NY/ ISR/ Medellin
212-666-6217
This is set-up to fly hard over the next 6-9 months
New trend, volume is here
GL
I have made nibble sells above $20, but given I sold afterhours some at $24.63, I may buy back a little as high as $22.50, I would not be completed surprised with $60 or more at any time in next 18 months
Yes... 212-666-6217 Neal Hugh Hurwitz, NY NY these days :)
Does that mean your entire position? Or just some of it?
Hi Neil, are you taking phone calls to discuss the company? I’d like to get some of your insight.
Thank you
I am a slow seller and sold most of my little sales this morning at $22.84 coincidentally. All depending though, I think $1 billion market cap may be on the low side but I wait for a couple more rounds or so of news to see how it is shaping up
20.12--- we need options for this thing :)
19.62--- good.
BUY.
After listening to the Florida doctor--- yes, the Zager presentation is important and the results in Europe I hear have been good...
this tech seems very important--- yes, my MD IR friend has said so always...
Seems like this should be priority review and approval by FDA.--- we need good results in the trials for FDA approval; possible 2021 I hear...
I’m not sure why this isn’t a buzz.--- Delcath history with FDA was not good and stock a disaster after $16---
as Sam knows, now is a new day.
Should be a BUY now as a spec. Upside possible is great.
After listening to the Florida doctor this tech seems very important step to fight met liver cancer. Even if it shrink the tumor enough for further resection and IO therapy to turn the tide.
Seems like this should be priority review and approval by FDA
I’m not sure why this isn’t a buzz.
What are your thoughts Neil?
Thanks
Holding now at 20--- exciting. We got in again when I spoke with Gil at 9...
Everyone should listen to the Zager presentation; he is in FL. And Europe has been using it.
They also raised $50 million as you know.
Now-------------- what are the medical trial results????
I will refrain from speculating on what this pps can be ahead :)
As a spec, it is a BUY.
Of course that $600M was like for a blink of an eye as the old product was overhyped in our minds as it did not filter well. We saw too many times it was a market cap of $1 million to $5 million so thus I am happy for those in now with the big boys as at least the possibility of winning is real.
You and I can recall when cap was $600 million :)
Med results have to be OK/good; FDA approval would rise this a lot!!!, maybe this year!
Rosalind is very positive and I like Gil! and he is very pleased with Michel.
Thanks for sharing this insight - I came in about 6 months ago and am holding for a similar outcome in 2022..
Followers
|
497
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50157
|
Created
|
05/11/05
|
Type
|
Free
|
Moderators |
In December 2018, Delcath entered into a License Agreement with medac GmbH for the commercialization of the CHEMOSAT® system in Europe. Under the terms of the medac License, medac has the exclusive right to sell and market CHEMOSAT® in all member states of the EU, Norway, Liechtenstein, Switzerland, and the United Kingdom.
Since launching CHEMOSAT® in Europe, over 750 commercial treatments have been performed at over 25 European cancer centers. Physicians in Europe have used CHEMOSAT® to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine.Split # | Date | Ratio |
1 | April 9, 2014 | 1:16 |
2 | July 21, 2016 | 1:16 |
3 | November 6, 2017 | 1:350 |
4 | May 2, 2018 | 1:500 |
5 | December 24, 2019 | 1:700 |
Common Shares Authorized: | 1,000,000,000 |
Common Shares Outstanding: | 70,056 |
Preferred Shares Authorized: | 10,000,000 |
Preferred Shares Outstanding: | 41,447 |
Warrants: | 29 | ($42; exp 2/2020 - 10/2021) |
2019 Warrants: | 1,826,579 | ($23.04; exp 12/2024) |
Options: | 1,640 | |
Total Warrants/Options: | 1,828,248 |
Preferred Stock: | 1,799,093 |
Convertible Notes: | 63,493 |
Total Reserved: | 1,862,586 |
Jennifer K. Simpson, Ph.D. | : 2,965 |
John Purpura, M.S. | : 2,830 |
William D. Rueckert | : 2,619 |
Roger G. Stoll, Ph.D. | : 4,047 |
Marco Taglietti, M.D. | : 2,606 |
Total Shares | : 21,459 |
Altium Capital Management L.P. | : 7,204 |
Rosalind Master Fund L.P. | : 7,024 |
Hudson Bay Master Fund Ltd. | : 7,024 |
Total Shares | : 21,612 |
45 Shareholders (est.) | : 26,985 |
Company Website: Delcath Systems, Inc. | Stock and Financial Website: OTC Marketplace |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |